Abstract

Summary Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin‐receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real‐world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.